What's Happening?
DBV Technologies, a biopharmaceutical company, has released its half-year report on the liquidity contract with ODDO BHF. The report details the transactions executed from January 1 to June 30, 2026, under the liquidity contract, which is in accordance
with AMF Decision No. 2021-01. As of June 30, 2026, the liquidity account held 146,321 DBV Technologies shares and €396,088.22. During the first half of 2026, 1,989 buy transactions and 2,012 sales transactions were executed, involving 2,707,915 shares purchased for €8,836,273.65 and 2,636,174 shares sold for €8,704,457.81. DBV Technologies focuses on developing treatments for food allergies using its proprietary VIASKIN® patch technology, which aims to desensitize the immune system to allergens. The company is conducting clinical trials for its VIASKIN® Peanut Patch in young children with peanut allergies.
Why It's Important?
The liquidity contract results are significant as they reflect DBV Technologies' financial activities and market presence. The company's focus on developing treatments for food allergies addresses a critical unmet medical need, potentially impacting millions of individuals, particularly children, who suffer from food allergies. The VIASKIN® Peanut Patch represents a novel approach to allergy treatment, which could transform care standards and improve quality of life for patients. The financial transactions under the liquidity contract also indicate investor interest and confidence in DBV Technologies' market strategy and product development pipeline.
